What is NeuroMed's primary focus?

NeuroMed Pharmaceuticals focuses on developing treatments for neurological degenerative diseases, specifically offering Yac-101, a potential treatment for neuro-degeneration injuries.

When was NeuroMed founded?

NeuroMed was founded in January 2005.

What is the current status of NeuroMed?

NeuroMed was acquired by Epirus Biopharmaceuticals in December 2009 and is currently inactive.

What was the total amount raised by NeuroMed?

NeuroMed raised a total of $1,000,000.

When was NeuroMed's last funding round?

NeuroMed's last funding round occurred in March 2012, raising $1,000,000.

What is the core technology behind NeuroMed's product Yac-101?

Yac-101 is based on specific and differentiating metal chelation, designed to prevent reactive oxygen species and maintain cellular functions like cytosolic calcium homeostasis and mitochondrial function.

Who acquired NeuroMed?

NeuroMed was acquired by Epirus Biopharmaceuticals in December 2009.

NeuroMed

NeuroMed Pharmaceuticals was developing Yac-101, a potential treatment for injuries involving neuro-degeneration.

Acquired by CombinatoRx

Acquired Jerusalem, Israel Founded 2005

Last updated 2026-07-20

Acquired by CombinatoRx, Dec 2009
Raised $1M PIPE, Feb 2012

Total raised

$1.0M

Last: Undisclosed Round 2012-03

Stage

Acquired

Founded

2005

Headcount

1-10

Jerusalem, Israel

Sector

—

About

NeuroMed Pharmaceuticals developed Yac-101, a drug candidate for neuro-degeneration based on metal chelation to prevent reactive oxygen species, maintain calcium homeostasis, preserve mitochondrial function, prevent cell membrane damage, and preserve energy stores. The company was acquired by CombinatoRx in December 2009, which then changed its name to Zalicus Pharmaceuticals. Zalicus was subsequently acquired by Epirus Biopharmaceuticals in July 2014, and later, the U.S. arm of Israel-based Taro Pharmaceuticals acquired Zalicus Pharmaceuticals Ltd. from Epirus Biopharmaceuticals in October 2015.

Funding history · 1 round · $1.0M total

2012-02

PIPE $1.0M

Q&A

What is NeuroMed's primary focus?: NeuroMed Pharmaceuticals focuses on developing treatments for neurological degenerative diseases, specifically offering Yac-101, a potential treatment for neuro-degeneration injuries.
When was NeuroMed founded?: NeuroMed was founded in January 2005.
What is the current status of NeuroMed?: NeuroMed was acquired by Epirus Biopharmaceuticals in December 2009 and is currently inactive.
What was the total amount raised by NeuroMed?: NeuroMed raised a total of $1,000,000.
When was NeuroMed's last funding round?: NeuroMed's last funding round occurred in March 2012, raising $1,000,000.
What is the core technology behind NeuroMed's product Yac-101?: Yac-101 is based on specific and differentiating metal chelation, designed to prevent reactive oxygen species and maintain cellular functions like cytosolic calcium homeostasis and mitochondrial function.
Who acquired NeuroMed?: NeuroMed was acquired by Epirus Biopharmaceuticals in December 2009.

Sectors & technology

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Technologies

BiologicalsCells

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticals

Business model

B2B

Highlights

1 Patents

External links

LinkedIn	linkedin.com/company/8666871

Identifiers & details

Former names	CombinatorX, NeuroMed
Founded	2005-1
Status reason	Acquired (Inactive) by Epirus Biopharmaceuticals on Dec 2009 - closed due to acquisition

Acquisitions & public offerings

Acquired by CombinatoRx 2009-12

Radar intelligence

Patents

EPO	60

Publications (Crossref)

Works	10